Oruka Therapeutics Q3 2026 net loss widens 65% to $49.97 million
ORKA•Oruka Therapeutics’ third-quarter 2026 net loss widened 65% year over year to $49.97 million, while cash, cash equivalents and marketable securities totaled $1.2 billion at September 30. ORKA-001’s high-dose group achieved 61% PASI 100 at Week 16 in EVERLAST-B, and Phase 3 trials are planned for the first half of 2027.
1. Quarterly results
Oruka Therapeutics’ third-quarter 2026 net loss widened 65% year over year to $49.97 million. Research and development expenses climbed 85% to $53.7 million, primarily due to additional clinical trials and higher employee compensation expenses. Cash, cash equivalents and marketable securities totaled $1.2 billion at September 30, 2026.
2. ORKA-001 results and plans
ORKA-001’s high-dose group achieved 61% PASI 100 at Week 16 in EVERLAST-B, consistent with EVERLAST-A results. Oruka plans ORKA-001 Phase 3 trials for the first half of 2027 and expects EVERLAST-A 52-week data in December 2026.
